Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
A form includes dropdowns for selecting a state, zip code, and country, with California pre-selected as the default state and the United States as the default country.
New insider De Verneuil Vanina claimed ownership of 65,120 units of Common Stock (SEC Form 3)
Vir Biotechnology appoints Jennifer Towne, Ph.D., as Executive VP and Chief Scientific Officer effective Nov 6, 2023, leading research from basic to clinical stages.
Cubist Systematic Strategies LLC Grows Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)
Cubist Systematic Strategies LLC increased its Vir Biotechnology holdings by 6,402% in Q2, owning 188,624 shares worth $1,679,000. Other investors also adjusted their stakes, with Point72 DIFC Ltd, Magnetar Financial LLC, Public Sector Pension Investment Board, XTX Topco Ltd, and Hsbc Holdings PLC making notable changes. Director Janet Napolitano sold 12,190 shares at $7.80 each. Analysts have a 'Moderate Buy' consensus rating for VIR, with an average price target of $36.80.
Vir Biotechnology (NASDAQ:VIR) Sets New 12-Month Low at $7.13
Vir Biotechnology hit a new 52-week low trading at $7.13, with analysts rating it 'Moderate Buy' and an average price target of $36.80. The company reported a revenue decline and missed earnings estimates, while insiders and institutional investors made significant stock transactions.
SWOT analysis: strategic focus drives stock potential amid financial challenges
VIR Biotechnology focuses on HDV, HBV, and T-cell engagers, with promising clinical data and strategic licensing deals, positioning it for growth in infectious disease treatment. Financial challenges include negative EPS estimates and high cash burn, but analysts remain optimistic about its potential in HDV and HBV markets.
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Profund Advisors LLC
Profund Advisors LLC reduced its Vir Biotechnology stake by 57.6% in Q2. Other investors adjusted their holdings, with Charles Schwab and Vanguard increasing stakes. Vir Biotechnology's stock opened at $7.53, with a market cap of $1.03 billion. The company reported a Q2 revenue of $3.08 million, missing expectations. Director Janet Napolitano sold 12,190 shares. Analysts set a consensus 'Moderate Buy' rating with a target price of $36.80.
© Copyright 2024. All Rights Reserved by MedPath